Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research note released on Thursday. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

NYSE OGEN opened at $0.31 on Thursday. Oragenics has a 1-year low of $0.25 and a 1-year high of $4.95. The company has a market cap of $3.75 million, a PE ratio of -0.04 and a beta of 0.40. The stock’s 50 day simple moving average is $0.33 and its 200-day simple moving average is $0.58.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.